TMB, MSIsensor score, mutational signatures and recurrent non-synonymous somatic mutations identified by whole-exome sequencing in endometrial cancers with clinical benefit (PFS 24 weeks) and without clinical benefit (PFS < 24 weeks). Cases are represented by columns and genes by rows. Only pathogenic mutations are shown. MSI status, dominant mutational signature, histologic types and mutation types are color-coded according to the legend. Percentages in bold indicate statistically significantly different. * P < 0.05, two-sided Fisher's exact test. First, dominant mutational signature; Second, secondary mutational signature.
